The provided source explores the increasing use of GLP-1 receptor agonists like semaglutide and liraglutide in individuals with HIV. It highlights that these medications are beneficial for addressing obesity and metabolic syndrome, common issues exacerbated by antiretroviral therapy, by promoting weight loss, especially visceral fat,…
A Washington Post article talks about the Trump administration experiment to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs like Ozempic, potentially benefiting millions of Americans struggling with obesity. This initiative, a reversal of a previous stance, aims to improve patient metabolic…
The provided text describes glucagon-like peptide-1 (GLP-1), detailing its production and the wide array of organs and systems it affects. Primarily, GLP-1 is generated in the intestinal L-cells and the brainstem’s nucleus of the solitary tract (NTS). Its influence is extensive, as GLP-1…
This JAMA article provides comprehensive guidance for clinicians on integrating diet and physical activity when prescribing GLP-1 receptor agonists for weight management. It outlines strategies for monitoring and managing both insufficient and excessive weight loss, emphasizing individualized approaches. The text details nutritional assessment and…
This patient-focused guide from JAMA Internal Medicine provides essential information for individuals utilizing GLP-1 medications for weight loss. It outlines the medications’ functions and offers practical dietary advice through a “MEAL” plan, emphasizing muscle maintenance, energy balance, side effect avoidance, and adequate liquid intake. Furthermore, the document provides exercise recommendations to…
The practice of compounding pharmacies adding various supplements to GLP-1 receptor agonist formulations like semaglutide or tirzepatide is very common in the United States. These additions, which often include vitamins, amino acids, and other compounds, are marketed under the pretense of enhancing…
“FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications. It highlights how temporary shortages of these drugs led to a surge in unregulated “knock-offs” from…
A systematic review investigating the relationship between adiposity measures and the risk of developing colorectal cancer (CRC), building upon existing research that often relies solely on Body Mass Index (BMI). The review synthesizes findings from fifteen articles across ten studies, utilizing various body composition measurement…
This source explores the impact of semaglutide, a weight loss medication, on muscle mass, glucose regulation, and bone health in adults with obesity. It highlights that muscle loss is a common consequence of weight reduction, particularly with semaglutide, and this…
This academic article presents a cost-effectiveness analysis of tirzepatide, a medication for managing overweight and obesity, comparing it against lifestyle modification (LSM) alone. Researchers used a simulation model to project lifetime health outcomes and costs for patients, focusing on complications like cardiovascular events, type 2 diabetes, cancer, osteoarthritis,…